In summary, EDA, a hepatokine, may be associated with a variety of diseases, such as metabolic disorders, DN, and cancer, and may be a link among insulin resistance, T2DM, obesity, and NAFLD. This evidence concerns the gene EDA and metabolic dysfunction-associated steatotic liver disease.